Overview: Pax8 TestIntroduction: The Pax8 Test detects Pax8 expression to diagnose thyroid or kidney cancers, causing lumps or weight loss. Following 2023 ASCO guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected thyroid or kidney cancers, such as papillary thyroid carcinoma or renal cell carcinoma.
Other Names: Pax8 Assay, Thyroid/Kidney Cancer Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Pax8 testing began in the 2000s with thyroid cancer research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects Pax8 expression to diagnose thyroid or kidney cancers, guides treatment, and evaluates patients with lumps or weight loss.
Test Parameters: 1. Pax8 Expression
Pretest Condition: No fasting required. Collect serum or plasma. Report history of lumps, weight loss, or cancer symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document lumps, weight loss, or family history of thyroid/kidney cancers. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of sample collection.
Procedural Considerations: Uses immunofluorescence assay (IFA) to detect Pax8 expression. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for thyroid or kidney cancer diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Low Pax8 expression may reduce sensitivity.
Clinical Significance: Positive Pax8 expression confirms thyroid or kidney cancer, guiding surgery or targeted therapy. Negative results may require tissue biopsy.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Thyroid ultrasound, renal CT, or tumor markers to confirm thyroid/kidney cancer diagnosis.
Test Limitations: Non-specific for certain cancer types; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Thyroid Cancer Guidelines, 2023; Journal of Clinical Oncology, Nonaka D, 2022.
